Fig. 1 · Structure

Documents & Downloads

Geraniin

Cat. No. A14716 CAS 60976-49-0
Geraniin is a dehydroellagitannin found in geraniums.

In Stock

Publications for Geraniin

1 publication citing this product

  1. Maxime Delisle‐Houde, .et al. , Annals of Applied Biology, 2020, 177(1): 51-60

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Geraniin inhibited recombinant human Hsp90α ATPase activity in a concentration-dependent manner at 2, 10 and 50 µM. The assay included 17-AAG and hardwickiic acid as positive and negative comparators. These biochemical data do not establish target selectivity or prove that Hsp90 inhibition accounts for every cellular effect. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
A549 ED50 > 10 μg/mL Cytotoxicity against human A549 cells by tetrazolium salt-based colorimetric assay [PMID: 1431932]
HCT-8 ED50 > 10 μg/mL Cytotoxicity against human HCT8 cells by tetrazolium salt-based colorimetric assay [PMID: 1431932]
Huh-7 EC50 33.19 μM Antiviral activity against Hepatitis C virus infected in human Huh7.5 cells assessed as inhibition of viral replication after 96 hrs by quantitative RT-PCR analysis [PMID: 22196120]
Huh-7 CC50 63.4 μM Cytotoxicity against human Huh7.5 cells after 96 hrs by MTT assay [PMID: 22196120]
KB ED50 > 10 μg/mL Cytotoxicity against human KB cells by tetrazolium salt-based colorimetric assay [PMID: 1431932]
RD IC50 10 μg/mL Antiviral activity against C4 type Human enterovirus 71 FY0805 infected in human RD cells assessed as inhibition of viral replication by plaque reduction assay [PMID: 22342145]
TE-671 ED50 > 10 μg/mL Cytotoxicity against human TE671 cells by tetrazolium salt-based colorimetric assay [PMID: 1431932]

Geraniin Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Geraniin from 2 published references. In vitro models include recombinant human Hsp90α.

Geraniin In Vitro Studies

In a 24-h MTT assay, geraniin reduced HeLa and Jurkat cell viability, with reported IC50 values of 5.1±0.2 µM and 0.76±0.1 µM, respectively. PHA-stimulated human PBMC showed much smaller viability reductions over the tested range, although high-concentration effects were observed. This cell comparison does not establish clinical efficacy or general safety. [1]

Inhibition of recombinant Hsp90α ATPase

Biochemical assay · Recombinant human Hsp90α [1]

Geraniin reduced ATPase activity in a concentration-dependent manner. 17-AAG was the positive comparator and hardwickiic acid (HA) the negative comparator; activity was normalized to untreated enzyme.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Residual Hsp90α ATPase activity relative to untreated enzymeQualitative concentration response Concentration-dependent inhibition at 2, 10 and 50 µM; HA retained near untreated activity[1]

Literature-Reported Treatment Conditions

Treatment concentration
2, 10 and 50 µM (Figure 3A)
Exposure duration
60 min
Method
ATP hydrolysis assay at 40°C with 40 nM Hsp90α and 100 µM ATP; ADP Hunter Plus fluorescence readout
Reported limits
Final solvent content for this ATPase assay is not specified in the read assay subsection; no numerical IC50 was reported there or in Figure 3A.
Methods and source locations

Compound reported in the paper: Geraniin; Compound label in the paper: Compound 54

Literature on geraniin; does not establish activity, purity or stability of an Adooq lot.

Materials: ATP Hydrolysis Inhibition; Results: Inhibition of Hsp90α by Geraniin; Figure 3A and caption

Residual Hsp90α ATPase activity relative to untreated enzyme: Fluorescence measurement of ADP generation; untreated enzyme set to 100%; background lacking enzyme or substrate subtracted — Figure 3A and caption; ATP Hydrolysis Inhibition

Geraniin effects on HeLa, Jurkat and PBMC viability

Cell-based study · HeLa epithelial carcinoma cells, Jurkat leukemia cells and PHA-stimulated human peripheral blood mononuclear cells (PBMC) [1]

After 24 h, geraniin reduced the MTT viability endpoint in HeLa and Jurkat cells. PBMC were less affected over the tested range; this comparator does not establish general safety.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HeLa viability after geraniin exposureIC50 5.1±0.2 µM[1]
Jurkat viability after geraniin exposureIC50 0.76±0.1 µM[1]
PHA-stimulated PBMC viability comparatorQualitative response Much smaller viability reduction than in the cancer cell lines across 0.5–50 µM; effects at high concentrations were not absent[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5–50 µM geraniin
Exposure duration
24 h
Method
Cell exposure followed by MTT conversion assay; trypan-blue exclusion described as an additional viability assessment
Vehicle
0.10% (v/v) DMSO; vehicle-treated cells are the survival reference
Co-treatment
None; 17-AAG tested separately as comparator
Reported limits
Cellular geraniin stability/metabolite composition not established in this experiment; ± values are reproduced as reported, with general statistical reporting as mean ± SD, without assuming independent donor n.
Methods and source locations

Compound reported in the paper: Geraniin; Compound label in the paper: Compound 54

Literature on geraniin; does not establish activity, purity or stability of an Adooq lot.

Cell Culture and Treatment; Cell Proliferation and Viability; Results: Effect of Geraniin on Cancer Cell Viability; Figure 5A and caption

HeLa viability after geraniin exposure: 24-h MTT viability dose-response relative to 0.10% DMSO control — Results: Effect of Geraniin on Cancer Cell Viability; Figure 5A; Cell Proliferation and Viability

Jurkat viability after geraniin exposure: 24-h MTT viability dose-response relative to 0.10% DMSO control — Results: Effect of Geraniin on Cancer Cell Viability; Figure 5A; Cell Proliferation and Viability

PHA-stimulated PBMC viability comparator: Figure 5A comparison; Results additionally describe minimal high-dose cytotoxic effects by trypan-blue exclusion — Figure 5A; Results: Effect of Geraniin on Cancer Cell Viability

Geraniin In Vivo Studies

In male Sprague Dawley rats fed a high-fat diet for 10 weeks, oral geraniin supplementation at 10 or 50 mg/kg body weight during the final 4 weeks lowered serum malondialdehyde and protein carbonyl content versus HFD controls. HFD alone did not significantly increase malondialdehyde versus normal diet, and the treated doses did not differ significantly for that endpoint. Liver changes were reported at 50 mg/kg; individual grading also records abnormalities at 10 mg/kg despite a normal-group narrative description. The experiment does not establish systemic exposure to intact geraniin or general organ safety. [2]

Serum oxidative-damage markers and organ limits in HFD-fed rats

Animal study · Male Sprague Dawley rats; four randomized groups, n=8/group; normal diet (ND), high-fat diet (HFD), HFD plus geraniin 10 or 50 mg/kg body weight [2]

Four weeks of geraniin supplementation during a 10-week HFD experiment lowered serum MDA and protein carbonyl content versus HFD controls. HFD alone did not significantly elevate MDA versus ND. Liver histology limits broad safety interpretation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fasting serum malondialdehyde at week 10Mean ± SEM ND 2.142±0.123; HFD 1.984±0.039; HFD+10 mg/kg 1.408±0.058; HFD+50 mg/kg 1.378±0.089 nmol/mL[2]
Fasting serum protein carbonyl content at week 10Mean ± SEM ND 5.909±0.001; HFD 6.988±0.004; HFD+10 mg/kg 5.227±0.001; HFD+50 mg/kg 4.773±0.001 nmol/mL[2]
Liver morphology at week 10Reported adverse/limiting observation Authors report focal central-vein congestion and scattered periportal inflammation at 50 mg/kg. Table 5 also records abnormalities in some 10 mg/kg animals despite normal-group prose.[2]

Conditions shared by the study groups

Route
Oral (feeding/supplementation as reported)
Treatment course
Weeks 7–10 (4 weeks) during 10-week HFD feeding
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
HFD + 10 mg/kg geraniin
10 mg/kg body weight
HFD-only group; normal-diet group as additional comparatorSerum MDA and PCC below HFD controls at week 10. Liver morphology must be interpreted with Table 5/prose discrepancy; no general safety conclusion.[2]
HFD + 50 mg/kg geraniin
50 mg/kg body weight
HFD-only group; normal-diet group as additional comparatorSerum MDA and PCC below HFD controls at week 10. Liver morphology must be interpreted with Table 5/prose discrepancy; no general safety conclusion.[2]
HFD + 10 mg/kg geraniin
Model: Male Sprague Dawley rats, n=8 in treatment group
Reported limits: Exact oral delivery technique, vehicle and dosing frequency are not specified in the read Dietary Treatments section.
HFD + 50 mg/kg geraniin
Model: Male Sprague Dawley rats, n=8 in treatment group
Reported limits: Exact oral delivery technique, vehicle and dosing frequency are not specified in the read Dietary Treatments section.
Methods and source locations

Compound reported in the paper: Geraniin

Literature on geraniin; does not establish activity, purity or stability of an Adooq lot.

Materials and Methods: Preparation of Geraniin, Animals and Housing, Dietary Treatments, serum assays, Statistical Analysis; Results Tables 1 and 5; Liver histology and Figure 4

Fasting serum malondialdehyde at week 10: Serum MDA immunoassay; n=8/group in experiment. Table 1 letters show both treated groups differ from ND and HFD (p<0.05), without significant dose-group difference. HFD versus ND not significant. — Table 1 and footnote; Results: Effect of High-Fat Feeding and Geraniin Treatment on Oxidative Damage Biomarkers; Statistical Analysis

Fasting serum protein carbonyl content at week 10: Protein carbonyl assay via hydrazone formation; n=8/group in experiment. Table 1 letters indicate both treated groups below HFD (p<0.05); no significant difference between the treated doses is marked. — Table 1 and footnote; Quantification of Oxidative Damage Biomarkers; Statistical Analysis

Liver morphology at week 10: Blinded H&E assessment; Figure 4 image and caption viewed with individual grading in Table 5; qualitative descriptions only, no independent diagnostic or incidence estimate from images. — Results: Liver; Figure 4 and caption; Table 5; Discussion liver paragraphs

HFD + 10 mg/kg geraniin · Dietary Treatments; Animals and Housing; Tables 1 and 5; Liver results

HFD + 50 mg/kg geraniin · Dietary Treatments; Animals and Housing; Tables 1 and 5; Liver results

Specifications

Manufacturer Adooq Bioscience
CAS Number 60976-49-0
Formula C41H28O27
Molecular Weight 952.64
SMILES
OC1=C(O)C(O)=C(C(C(O)=C(O)C(O)=C2)=C2C(O[C@H]3[C@@H]4OC(C(C=C(O)C(O)=C5OC6(O)C(O)7O)=C5C7C8=CC6=O)=O)=O)C(C(OC[C@H](O[C@@H]4OC(C9=CC(O)=C(O)C(O)=C9)=O)[C@@H]3OC8=O)=O)=C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 96 mg/mL (100.77 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Geraniin Research References

  1. [1] Antonio Vassallo, Maria Carmela Vaccaro, Nunziatina De Tommasi, et al. Identification of the Plant Compound Geraniin as a Novel Hsp90 Inhibitor PLOS ONE (2013). PMID: 24066128 DOI: 10.1371/journal.pone.0074266 Source material
  2. [2] Alexis Panny Y. S. Chung, Sunil Gurtu, Srikumar Chakravarthi, et al. Geraniin Protects High-Fat Diet-Induced Oxidative Stress in Sprague Dawley Rats Frontiers in Nutrition (2018). PMID: 29616223 DOI: 10.3389/fnut.2018.00017 Source material

Publications

1 publication citing this product

  1. Maxime Delisle‐Houde, .et al. , Annals of Applied Biology, 2020, 177(1): 51-60

Added to your cart

View Cart Checkout
Loading...